Format

Send to

Choose Destination
Nat Rev Urol. 2009 Apr;6(4):216-22. doi: 10.1038/nrurol.2009.25.

Sildenafil citrate for female sexual arousal disorder: a future possibility?

Author information

1
Robert Wood Johnson University Hospital, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA. corina.schoen@gmail.com

Abstract

Female sexual arousal disorder (FSAD) is a common disorder encountered in clinical practice, with self-reported arousal difficulties reported in up to 26% of American women. Various oral therapies for FSAD have been studied, including sildenafil citrate, a phosphodiesterase inhibitor that is currently used to treat male erectile dysfunction. In vitro studies of sildenafil citrate have demonstrated smooth-muscle relaxation in clitoral tissue, and phosphodiesterase type-5 has been shown to be present in vaginal, clitoral and labial smooth muscle; these findings have led to theories that sildenafil citrate might be successful for treating FSAD. This Review discusses the data from clinical trials that have assessed sildenafil citrate for the treatment of FSAD; the trials show that sildenafil citrate is moderately effective. Sildenafil citrate may also be effective in women with FSAD secondary to multiple sclerosis, diabetes or antidepressant use; however, more trials in these patient populations are required to confirm these findings.

PMID:
19352396
DOI:
10.1038/nrurol.2009.25
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center